Levetiracetam Injection, Solution, Concentrate
Product Images NDC 72162-2638

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72162-2638). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622638)

This text provides information about a pharmaceutical product containing 500 mg of levetiracetam per vial for intravenous use. The solution also includes sodium acetate trihydrate, sodium chloride, and glacial acetic acid. It emphasizes the need for dilution before administration and proper storage conditions. The dosage information and storage guidelines are clearly outlined, with a reminder to keep the product out of reach of children. Additionally, it mentions a QR code for complete dosage recommendations.*

FDA Label Image

Levet-inj-figure-1 (Levet Inj Figure 1)

This text shows the percentages of 39.6% and 37.1% relating to patient data in a study involving a placebo group and two different dosages of Levetiracetam medication. The study includes patient numbers for each group, such as 95 for the placebo, 97 for Levetiracetam 1000 mg/day, and 101 for Levetiracetam 3000 mg/day.*

FDA Label Image

Levet-inj-figure-2 (Levet Inj Figure 2)

This is not available.*

FDA Label Image

Levet-inj-figure-3 (Levet Inj Figure 3)

This text provides percentages for two groups - 39.4% and 14.4%, along with the number of participants for each group (104 for Placebo and 180 for Levetiracetam 3000 mg/day). This appears to be a comparison between the effectiveness or outcomes of the two groups.*

FDA Label Image

Levet-inj-figure-4 (Levet Inj Figure 4)

This text shows the comparison of the effectiveness of a placebo and levetiracetam in a study involving 97 individuals in the placebo group and 101 individuals in the levetiracetam group. The data is presented in percentages ranging from 0% to 45%, with the latter being the highest value attributed to the placebo group.*

FDA Label Image

Levet-inj-figure-5 (Levet Inj Figure 5)

The text provides percentages for a placebo group (43.1%) and another value (19.6%) for a group taking Levetiracetam. The sample size for the placebo group is 51, and for the Levetiracetam group, it is 58. These values might be part of a research study or clinical trial evaluating the effectiveness or side effects of Levetiracetam compared to a placebo.*

FDA Label Image

Levet-inj-figure-6 (Levet Inj Figure 6)

This text indicates percentage values from 100% to 70%, followed by a comparison of two groups: Placebo with 84 individuals and Levetiracetam with 79 individuals. The information seems to be related to a study or research comparing the effectiveness of a placebo versus Levetiracetam.*

FDA Label Image

Levet-inj-structure (Levet Inj Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.